Current Report Filing (8-k)
July 11 2017 - 5:21PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
Current
Report
Pursuant
to Section 13 or 15(d) of
the
Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): July 11, 2017
RESPIRERX
PHARMACEUTICALS INC.
(Exact
name of registrant as specified in its charter)
Delaware
|
|
1-16467
|
|
33-0303583
|
(State
or other jurisdiction
of
incorporation)
|
|
(Commission
File
Number)
|
|
(I.R.S
Employer
Identification
No.)
|
126
Valley Road, Suite C
Glen
Rock, New Jersey
|
|
07452
|
(Address
of principal executive offices)
|
|
(Zip
Code)
|
Registrant”s
telephone number, including area code: (201) 444-4947
(Former
name or former address, if changed since last report.)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
[ ]
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
[ ]
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company [ ]
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section
13(a)
of the Exchange Act. [ ]
Item
7.01 Regulation FD Disclosure
RespireRx
Pharmaceuticals Inc. (the “Company”) has prepared a platform summary and an executive summary with respect to each
of its two development platforms, Ampakines and Cannabinoids. The Cannabinoid Platform Summary describes the Company”s Dronabinol
program. The Ampakine Platform Summary describes the Company”s CX1739, CX717 and CX1942 programs. Each platform summary
is a very short overview of the platform, including a brief background section and a brief discussion of recent developments.
Each executive summary is a more extensive discussion of the respective platform, its related programs and potential applications,
including substantially more detailed scientific information. In addition, the Company has prepared a short Financial Summary
that summarizes certain recent market metrics and financial statement information, which financial statement information was drawn
from the Company”s annual report on Form 10-K for the year ended December 31, 2016 and its quarterly report on Form 10-Q
for the period ended March 31, 2017. Both platform summaries, both executive summaries and the Financial Summary are attached
as exhibits to this Current Report on Form 8-K.
Item
9.01 Financial Statements and Exhibits
(d)
Exhibits.
A
list of exhibits that are furnished and filed as part of this report is set forth in the Exhibit Index, which is presented elsewhere
in this document, and is incorporated herein by reference.
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
Date:
July 11, 2017
|
RESPIRERX
PHARMACEUTICALS INC.
|
|
|
|
|
By:
|
/s/
Jeff E. Margolis
|
|
|
Jeff
E. Margolis
Senior
Vice President, CFO, Treasurer and Secretary
|
EXHIBIT
INDEX
Exhibit
Number
|
|
Exhibit
Description
|
99.1
|
|
Ampakine
Platform Summary*
|
99.2
|
|
Cannabinoid
Platform Summary*
|
99.3
|
|
Ampakine
Executive Summary*
|
99.4
|
|
Cannabinoid
Executive Summary*
|
99.5
|
|
Financial
Summary*
|
*
Furnished herewith.
RespireRx Pharmaceuticals (CE) (USOTC:RSPI)
Historical Stock Chart
From Aug 2024 to Sep 2024
RespireRx Pharmaceuticals (CE) (USOTC:RSPI)
Historical Stock Chart
From Sep 2023 to Sep 2024